Obesity, diabetes, adiponectin and the kidney: a podocyte affair (Q37273056)

19 August 2017

1 reference

title

Obesity, diabetes, adiponectin and the kidney: a podocyte affair (English)

1 reference

19 August 2017

0 references

Carmine Zoccali

1

0 references

author name string

Francesca Mallamaci

series ordinal

2

1 reference

PubMed ID

18802210

19 August 2017

language of work or name

English

0 references

publication date

18 September 2008

1 reference

Nephrology Dialysis Transplantation

19 August 2017

1 reference

19 August 2017

23

1 reference

19 August 2017

12

1 reference

19 August 2017

3767-3770

1 reference

Prevalence of overweight and obesity in the United States, 1999-2004

19 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Obesity prevalence from a European perspective: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Screening for chronic kidney disease: where does Europe go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Body mass index and risk for end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Podocyte lesions in patients with obesity-related glomerulopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Insulin signalling downstream of protein kinase B is potentiated by 5'AMP-activated protein kinase in rat hearts in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Adiponectin and cardiovascular inflammatory responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Disruption of adiponectin causes insulin resistance and neointimal formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

High serum adiponectin levels during steroid-responsive nephrotic syndrome relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Adiponectin concentrations are influenced by renal function and diabetes duration in Pima Indians with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Adiponectin and cardiovascular disease: response to therapeutic interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Investigational therapies in the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

Adiponectin and renal disease progression: Another epidemiologic conundrum?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN517

21 January 2018

Identifiers

DOI

10.1093/NDT/GFN517

1 reference

19 August 2017

1 reference

PubMed ID

18802210